Literature DB >> 10800769

Cabergoline, prolactin and melatonin release at night in healthy men.

M Pacchioni, R Camisasca, M Caminiti, A C Andreotti, A E Pontiroli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10800769     DOI： 10.1007/BF03343693

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  8 in total

1.  Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients.

Authors:  C Ferrari; A Paracchi; C Romano; G Gerevini; M Boghen; A Barreca; P Fortini; A Dubini
Journal:  Clin Endocrinol (Oxf)       Date:  1988-11       Impact factor: 3.478

2.  Inhibition of presynaptic catecholamine synthesis with alpha-methyl-para-tyrosine attenuates nocturnal melatonin secretion in humans.

Authors:  R C Zimmermann; L Krahn; G Klee; P Delgado; S J Ory; S C Lin
Journal:  J Clin Endocrinol Metab       Date:  1994-10       Impact factor: 5.958

3.  Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.

Authors:  S Cannavò; L Curtò; S Squadrito; B Almoto; A Vieni; F Trimarchi
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

4.  Effect of apomorphine on melatonin secretion in normal subjects.

Authors:  S Lal; I Isaac; C Pilapil; N P Nair; N Hariharasubramanian; H Guyda; R Quirion
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1987       Impact factor: 5.067

5.  Dopamine inhibits melatonin synthesis in photoreceptor cells through a D2-like receptor subtype in the rat retina: biochemical and histochemical evidence.

Authors:  J Nguyen-Legros; E Chanut; C Versaux-Botteri; A Simon; J H Trouvin
Journal:  J Neurochem       Date:  1996-12       Impact factor: 5.372

6.  Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug.

Authors:  A E Pontiroli; L Cammelli; P Baroldi; G Pozza
Journal:  J Clin Endocrinol Metab       Date:  1987-11       Impact factor: 5.958

Review 7.  Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.

Authors:  C P Rains; H M Bryson; A Fitton
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

8.  Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers.

Authors:  A C Andreotti; E Pianezzola; S Persiani; M A Pacciarini; M Strolin Benedetti; A E Pontiroli
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.